

AR226-3757

RECEIVED

2007/05/15 11:51:14

445p

3M

May 17, 2007

Document Control Office
Docket AR-226
EPA East Building, Room 6428
1201 Constitution Avenue, N.W.
Washington, DC 20460
Phone: 202-564-8930
Attention: OPPT Docket No. AR-226 (Mary Dominiak - Room 4410)

Re: Information on Perfluorooctane Sulfonate, Perfluorooctanoic Acid, and Related Compounds

Dear Ms. Dominiak:

One of the documents in our May 10, 2007 submission contained some copying errors. Please substitute the enclosed good copy of the Final Report and Appendix, "The Effect of 3 Perfluorinated Alkyl Sulphonated on Cholesterol/Bile Acid Metabolism in 15%-Fat Fed E3-Leiden Transgenic Mice *In Vivo* and on Fatty Acid Conversion into Cholesterol in Rat Hepatocytes *In Vitro*" for the copy previously submitted. The study is not confidential.

Thank you very much for your assistance.

Very truly yours,



Michael A. Santoro
Director of Environmental Health
Safety and Regulatory Affairs
3M Center, Building 236-1B-10
St. Paul, MN 55144
651-733-6374 (phone)
651-733-1958 (fax)
E-mail: masantoro@mmm.com

cc: Dr. Jennifer Seed
Mr. John Linc Stine, MDH
Mr. James Kelly, MDH
Dr. Helen Goeden, MDH
(with enclosure)

CONTAINS NO CBI

304704

TNO-report

**THE EFFECT OF 3 PERFLUORINATED ALKYL
SULPHONATED ON CHOLESTEROL/BILE ACID
METABOLISM IN 15 %-FAT FED E3-LEIDEN
TRANSGENIC MICE *IN VIVO* AND ON FATTY ACID
CONVERSION INTO CHOLESTEROL IN RAT
HEPATOCYTES *IN VITRO*.**

Project / study number: 031.10074 / 3M-02

**TNO Quality of Life
TNO Biosciences**

Gaubius laboratory
Zernikedreef 9,
P.O. Box 2215
2301 CE Leliden
The Netherlands
Phone +31 71 518 1209
Fax +31 71 518 1901

Authors:
L.H. Cohen
E.J. Pieterman
E. Hoogee-de Nobel

In assignment of:
3M, Medical Department

Study monitor:
John L. Butenhoff, Ph.D., CIH, DABT
Corporate Scientist
Medical Department
3M Center, Building 0220-02-E-02
St. Paul, Minnesota 55144-1000
USA
Phone: +1.651.733.1962
Fax: +1.651.733.1773
E-mail: jbutenhoff@mmm.com

Study director:
Dr. Louis H. Cohen


Status and Date:
Final version: 04 December 2006

Previous versions:
Draft1: 18 October 2006
Draft2: 30 October 2006
Draft3: 28 November 2006

Number of pages: 35

Authorization by Dr. P.H.A. Quax,
Technology manager of Vascular and Metabolic Diseases:

Signature and date:



1 of 35

CONTAINS NO CBI



May 8, 2007

Document Control Office
Docket AR-226
EPA East Building, Room 6428
1201 Constitution Ave., N.W.
Washington, DC 20460
Phone: 202-564-8930
Attention: OPPT Docket No. AR-226 (Mary Dominiak - Room 4410)

Re: Information on Perfluorooctane Sulfonate, Perfluorooctanoic Acid, and Related Compounds

Dear Ms. Dominiak:

This continues 3M's voluntary submissions of data on perfluorooctane sulfonate (PFOS), perfluorooctanoic acid (PFOA), and related compounds. We are enclosing paper copies of the following:

- Final Report and Appendix, "The Effect of 3 Perfluorinated Alkyl Sulphonates on Cholesterol/Bile Acid Metabolism in 15%-Fat Fed E3-Leiden Transgenic Mice *In Vivo* and on Fatty Acid Conversion into Cholesterol in Rat Hepatocytes *In Vitro*." TNO Quality of Life, TNO Biosciences. December 4, 2006.
- Apelberg, Benjamin Joseph, "Fetal Exposure to Perfluorinated Compounds: Distribution and Determinants of Exposure and Relationships with Weight and Size at Birth," dissertation submitted to Johns Hopkins University (Lynn Goldman, thesis adviser), August 2006 (publicly available at Proquest.com dissertation service).
- Two DuPont documents produced to 3M by plaintiffs in litigation referencing retiree half-life data which corroborate 3M's retiree half-life study:
 - Playtis, A.J. "Washington Works C-8 Industrial Hygiene," 6/30/99 [half-life data is on the page stamped EID510286]; and
 - Playtis, A.J. E-mail to G.W. Jepson, et al., Re: Pensioner Blood Data, 8/8/00.

We also note that in a letter to the docket and agency officials dated February 2, 2007, Robert A. Bilott, counsel for Plaintiffs in civil litigation in Washington County, Minnesota (*Palmer, et al. v. 3M*), provided information regarding levels of perfluorochemicals in the blood

CONTAINING NO CBI

3

304526

serum of fifteen individuals in Minnesota. However, it appears ten of the samples submitted with the letter had already been submitted with prior letters:

SAMPLE NO.	SUBMISSION TO THE DOCKET
L7652-25	May 12, 2005 letter from Mr. Bilott
L7652-27	May 12, 2005 letter from Mr. Bilott
L7932-1	October 20, 2005 letter from Mr. Bilott
L7932-2	October 20, 2005 letter from Mr. Bilott
L7932-28	October 20, 2005 letter from Mr. Bilott
L7932-39	October 20, 2005 letter from Mr. Bilott
L7932-51	October 20, 2005 letter from Mr. Bilott
L7932-52	October 20, 2005 letter from Mr. Bilott
L7932-53	October 20, 2005 letter from Mr. Bilott
L7932-54	October 20, 2005 letter from Mr. Bilott

Please feel free to contact me with any questions.

Very truly yours,



Michael A. Santoro
 Director of Environmental Health
 Safety and Regulatory Affairs
 3M Center, Building 236-1B-10
 St. Paul, MN 55144
 651-733-6374 (phone)
 651-733-1958 (fax)
 E-mail: masantoro@mmm.com

Enclosures

cc: Dr. Jennifer Seed
 Mr. John Linc Stine, MDH
 Mr. James Kelly, MDH
 Dr. Helen Goeden, MDH